Erasca (ERAS) investor relations material

Pipeline overview and strategic focus

• Two main RAS-targeting molecules, ERAS-0015 (pan-RAS molecular glue) and ERAS-4001 (pan-KRAS inhibitor), are in phase 1 dose escalation trials, with data readouts expected in 2026 and next year, respectively.

• ERAS-0015 shows higher binding affinity and potency compared to benchmark molecules, with potential for improved tumor targeting and tolerability.

• ERAS-4001 demonstrates strong in vitro and in vivo activity against multiple KRAS mutations and wild type, with a unique scaffold and favorable PK properties.

• Naporafenib, a pan-RAF inhibitor, has shown improved efficacy and safety with rash prophylaxis and is currently in phase 3, with partnership discussions ongoing.

• ERAS-012, a bispecific antibody targeting EGFR domains 2 and 3, is in early discovery and aims to improve antitumor activity.

Competitive landscape and innovation

• The company leverages global innovation, in-licensing key molecules from China and focusing on generating robust U.S. clinical data.

• AI is being explored to streamline back office and regulatory processes, with ongoing evaluation of its broader impact on drug discovery.

• Regulatory interactions, especially with the FDA, have been positive, enabling rapid IND clearances for both RAS molecules.

• The evolving MFN policy is influencing partnership and commercialization strategies, shifting traditional models.

Clinical development and future plans

• ERAS-0015 phase 1 trial is enrolling well at five marquee sites, with a focus on safety, PK, and early efficacy at lower doses.

• Preclinical data suggest ERAS-0015 may offer better GI tolerability and manageable rash, with strategies in place for adverse event mitigation.

• Both monotherapy and combination strategies are being considered for RAS and KRAS programs, with flexibility to adapt based on clinical outcomes.

• ERAS-4001 is designed to overcome resistance by targeting both mutant and wild type KRAS, with activity against both GTP- and GDP-bound states.

• Combination of ERAS-0015 and ERAS-4001 is under consideration for risk mitigation and enhanced efficacy.